Replies to post #2634 on Ayala Pharmaceuticals Inc (ADXS)

[James salmon]

Really that is up to you. I have held ADXS stock for 3 years, through the highs and lows. We are currently at one of those lows. ADXS platform certainly has proved itself, but the RS thing was not timed well at all.

I have spoken to Dan O'conner several times, and I strongly believe he is the driving force behind ADXS current direction. He has a great track record, and will steer ADXS in the right direction.

Now Orphan drug status, as I said could go 1 of 3 ways. If ADXS can get Orphan status this would be a major event and we will see share price well above current levels. Orphan has been applied for 3 indications, so I expect we should get both head and neck and Anal cancer orphan status. Now re cervical this I am not so sure about, just because ADXS was turned down before. I know that they have not requested CIN this time and they believe they have submitted a strong case for Orphan status. Criteria has to be under 200,000 people, which includes those cured of the disease currently alive. I know a lot of work has go into this particular point, which is why it was turned down last time.

I continue to hold and add when I can, with a market cap of 19 million strong results so far, I know that 1 day I will be able to retire on my holding, it's just taken longer than I thought it would.

[James salmon]

Dollar,

I also hold INO as well, which has done very well over the last few months. If you look at the sort of news they have put out recently re animal trials and impact on share price this has had, you have to wonder why market cap of INO is around 200 million and Adxs is only 19 million with human trial results they have put out.

INO is very much in favor at the moment, ADXS is not, it really does make a difference.

INO though is a good company with a lot of promise.